Jun-Liang Fu
Overview
Explore the profile of Jun-Liang Fu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
1535
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yuan M, Song L, Wang Z, Zhang Z, Shi M, He J, et al.
Stem Cell Res Ther
. 2025 Feb;
16(1):94.
PMID: 40001244
Background: The long-term effects and outcomes of human mesenchymal stem cell (MSC) therapy in patients with severe coronavirus disease 2019 (COVID-19) remain poorly understood. This study aimed to evaluate the...
2.
Li B, Fan X, Cao W, Tian H, Wang S, Zhang J, et al.
Infect Dis Immun
. 2024 Apr;
1(2):74-85.
PMID: 38630120
Background: The ongoing global coronavirus disease 2019 (COVID-19) pandemic is posing a serious public health threat to nations worldwide. Understanding the pathogenesis of the disease and host immune responses will...
3.
Li T, Zhang B, Fang H, Shi M, Yao W, Li Y, et al.
EBioMedicine
. 2023 May;
92:104600.
PMID: 37149930
Background: Long-term effects of human mesenchymal stem cell (MSC) treatment on COVID-19 patients have not been fully characterized. The aim of this study was to evaluate the safety and efficacy...
4.
Shi L, Yuan X, Yao W, Wang S, Zhang C, Zhang B, et al.
EBioMedicine
. 2021 Dec;
75:103789.
PMID: 34963099
Background: The long-term consequences of human umbilical cord-derived mesenchymal stem cell (UC-MSC) treatment for COVID-19 patients are yet to be reported. This study assessed the 1-year outcomes in patients with...
5.
Meng F, Zhao J, Tan A, Hu W, Wang S, Jin J, et al.
Hepatol Int
. 2021 Dec;
15(6):1402-1412.
PMID: 34850325
Background & Aims: Immunotherapy with hepatitis B virus (HBV)-specific TCR redirected T (HBV-TCR-T) cells in HBV-related hepatocellular carcinoma (HBV-HCC) patients after liver transplantation was reported to be safe and had...
6.
Shi M, Li Y, Xu R, Meng F, Yu S, Fu J, et al.
Hepatol Int
. 2021 Nov;
15(6):1431-1441.
PMID: 34843069
Background: Mesenchymal stem cell (MSC) infusion was reported to improve liver function in patients with decompensated liver cirrhosis (DLC); however, whether the medication can improve outcome of these patients is...
7.
Fan J, Fu J, Wang F
Cell Mol Immunol
. 2021 Nov;
18(12):2586-2587.
PMID: 34782758
No abstract available.
8.
Shi L, Huang H, Lu X, Yan X, Jiang X, Xu R, et al.
Signal Transduct Target Ther
. 2021 Feb;
6(1):58.
PMID: 33568628
Treatment of severe Coronavirus Disease 2019 (COVID-19) is challenging. We performed a phase 2 trial to assess the efficacy and safety of human umbilical cord-mesenchymal stem cells (UC-MSCs) to treat...
9.
Zhang J, Wang X, Xing X, Xu Z, Zhang C, Song J, et al.
Nat Immunol
. 2020 Aug;
21(9):1107-1118.
PMID: 32788748
In coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the relationship between disease severity and the host immune response is not fully understood. Here...
10.
Song J, Lam S, Fan X, Cao W, Wang S, Tian H, et al.
Cell Metab
. 2020 Jul;
32(2):188-202.e5.
PMID: 32610096
The coronavirus disease 2019 (COVID-19) pandemic presents an unprecedented threat to global public health. Herein, we utilized a combination of targeted and untargeted tandem mass spectrometry to analyze the plasma...